**5. Conclusions**

As demand for glaucoma care increases, there will be a need for telehealth. Just as radiologists review scans remotely, ophthalmologists can review results and risk-stratify patients. A glaucoma suspect can be monitored remotely, provided that one has access to an OCT or visual field machine yearly. A patient with well-controlled mild to moderate glaucoma can also be monitored remotely if one has IOP measurements performed regularly and that an in-person dilated examination is performed annually. A patient with uncontrolled or severe glaucoma should have face-to-face visits, as there is much less room for error and a high likelihood of needing laser or surgical procedures. This algorithm for remote monitoring is illustrated in Figure 1. Essentially, face-to-face examinations can be limited to confirmation of diagnosis, management of patients with uncontrolled or severe glaucoma, and patients with new, concerning ocular symptoms. The telehealth approach is cost-effective and can increase patient satisfaction by decreasing waiting time during visits. Telehealth is particularly beneficial for patients in rural areas who have limited access to care and in the setting of a pandemic, when social distancing is enforced and the number of appointments is severely limited to reduce disease spread. Deep learning artificial intelligence will play an increasing role in the diagnosis and management of glaucoma using data extracted from telehealth.

**Figure 1.** Algorithm for Remote Monitoring. IOP: intraocular pressure. OCT: Optical coherence tomography.

**Author Contributions:** Conceptualization, S.H.W. and J.C.T.; methodology, S.H.W. and J.C.T.; software, S.H.W.; validation, S.H.W. and J.C.T.; formal analysis, S.H.W.; investigation, S.H.W. and J.C.T.; resources, S.H.W. and J.C.T.; data curation, S.H.W. and J.C.T.; writing—original draft preparation, S.H.W.; writing—review and editing, S.H.W. and J.C.T.; visualization, S.H.W. and J.C.T.; supervision, J.C.T.; project administration, J.C.T.; funding acquisition, J.C.T. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported in part by a Challenge Grant award from Research to Prevent Blindness, New York.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** S.H.W. declares no conflict of interest. J.C.T. is a consultant for Eyenovia, ReNetX Bio, and SmartLens and has equity interest in Ocutrx and SmartLens. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**Consultant:** Eyenovia: ReNetX Bio, SmartLens. Equity Interest: Ocutrx, SmartLens.

#### **References**

